• FDA grants Orphan Drug Designation for etoposide toniribate americanpharmaceuticalreview
    February 26, 2019
    Mundipharma EDO GmbH and Imbrium Therapeutics announced the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.
PharmaSources Customer Service